These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 29034584)

  • 21. Sphingolipids in ocular inflammation.
    Chan AY; Mann SN; Chen H; Stone DU; Carr DJ; Mandal NA
    Adv Exp Med Biol; 2014; 801():623-9. PubMed ID: 24664751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoregulatory role of ocular macrophages: the macrophages produce RANTES to suppress experimental autoimmune uveitis.
    Sonoda KH; Sasa Y; Qiao H; Tsutsumi C; Hisatomi T; Komiyama S; Kubota T; Sakamoto T; Kawano Y; Ishibashi T
    J Immunol; 2003 Sep; 171(5):2652-9. PubMed ID: 12928419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.
    Luo L; Yang J; Oh Y; Hartsock MJ; Xia S; Kim YC; Ding Z; Meng T; Eberhart CG; Ensign LM; Thorne JE; Stark WJ; Duh EJ; Xu Q; Hanes J
    J Control Release; 2019 Feb; 296():68-80. PubMed ID: 30660629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement, innate immunity and ocular disease.
    Sohn JH; Bora PS; Jha P; Tezel TH; Kaplan HJ; Bora NS
    Chem Immunol Allergy; 2007; 92():105-114. PubMed ID: 17264487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroinflammation in Retinitis Pigmentosa, Diabetic Retinopathy, and Age-Related Macular Degeneration: A Minireview.
    Massengill MT; Ahmed CM; Lewin AS; Ildefonso CJ
    Adv Exp Med Biol; 2018; 1074():185-191. PubMed ID: 29721943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene delivery of a viral anti-inflammatory protein to combat ocular inflammation.
    Ildefonso CJ; Jaime H; Rahman MM; Li Q; Boye SE; Hauswirth WW; Lucas AR; McFadden G; Lewin AS
    Hum Gene Ther; 2015 Jan; 26(1):59-68. PubMed ID: 25420215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular pathology of macrophages and interleukin-17 in age-related macular degeneration.
    Chan CC; Ardeljan D
    Adv Exp Med Biol; 2014; 801():193-8. PubMed ID: 24664698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melatonin: Implications for Ocular Disease and Therapeutic Potential.
    Scuderi L; Davinelli S; Iodice CM; Bartollino S; Scapagnini G; Costagliola C; Scuderi G
    Curr Pharm Des; 2019; 25(39):4185-4191. PubMed ID: 31724508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the Gut-Eye Axis: An Emerging Strategy to Face Ocular Diseases.
    Campagnoli LIM; Varesi A; Barbieri A; Marchesi N; Pascale A
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re-programming immunosurveillance in persistent non-infectious ocular inflammation.
    Epps SJ; Boldison J; Stimpson ML; Khera TK; Lait PJP; Copland DA; Dick AD; Nicholson LB
    Prog Retin Eye Res; 2018 Jul; 65():93-106. PubMed ID: 29530739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration.
    Handa JT; Bowes Rickman C; Dick AD; Gorin MB; Miller JW; Toth CA; Ueffing M; Zarbin M; Farrer LA
    Nat Commun; 2019 Jul; 10(1):3347. PubMed ID: 31350409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis.
    Barry RJ; Tallouzi MO; Bucknall N; Mathers JM; Murray PI; Calvert MJ; Moore DJ; Denniston AK
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012577. PubMed ID: 30562409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.
    Taylor AW; Kaplan HJ
    Ocul Immunol Inflamm; 2010 Dec; 18(6):488-92. PubMed ID: 21091058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulating of ocular inflammation with macrophage migration inhibitory factor is associated with notch signalling in experimental autoimmune uveitis.
    Yang H; Zheng S; Mao Y; Chen Z; Zheng C; Li H; Sumners C; Li Q; Yang P; Lei B
    Clin Exp Immunol; 2016 Feb; 183(2):280-93. PubMed ID: 26400205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic review of biologics for the treatment of noninfectious uveitis.
    Takeuchi M
    Immunotherapy; 2013 Jan; 5(1):91-102. PubMed ID: 23256801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Road to fulfilment: taming the immune response to restore vision.
    Dick AD
    Ophthalmic Res; 2012; 48(1):43-9. PubMed ID: 22398563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoimmune and autoinflammatory mechanisms in uveitis.
    Lee RW; Nicholson LB; Sen HN; Chan CC; Wei L; Nussenblatt RB; Dick AD
    Semin Immunopathol; 2014 Sep; 36(5):581-94. PubMed ID: 24858699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranibizumab: treatment in patients with neovascular age-related macular degeneration.
    Pieramici DJ; Avery RL
    Expert Opin Biol Ther; 2006 Nov; 6(11):1237-45. PubMed ID: 17049020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent developments in the treatment of age-related macular degeneration.
    Holz FG; Schmitz-Valckenberg S; Fleckenstein M
    J Clin Invest; 2014 Apr; 124(4):1430-8. PubMed ID: 24691477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan: A multicenter study.
    Takeuchi M; Kanda T; Kaburaki T; Tanaka R; Namba K; Kamoi K; Maruyama K; Shibuya E; Mizuki N
    Medicine (Baltimore); 2019 Mar; 98(9):e14668. PubMed ID: 30817592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.